Poster 2013: The safety of the united allergy services immunotherapy protocol

Background A small, but significant number of subcutaneous immunotherapy (SCIT) based systemic reactions (SR) result in morbidity and mortality. SR range from 4 to 7% for traditional protocols and up to 34% if undergoing RUSH immunotherapy. There is estimated 1 death per 2.5 million immunotherapy injections. We report the results of an IRB approved study and contrast the safety of the United Allergy Services (UAS) SCIT treatment protocol to previously published reports. We hypothesized that a slower SCIT build up phase and pre-selection for low risk patients would prove to be safer than traditional protocols.